Why FTSE 100 giant Astrazeneca is listing in New York

This week, one of the most valuable members of the FTSE 100 said it would be listing in New York in order to, as the company put it, “access the broadest available pool of capital.” AstraZeneca said it would float its shares on the New York Stock Exchange by “upgrading” its existing US equity listing of American depository receipts on the Nasdaq to a direct listing. The firm’s shares will now be traded across the London Stock Exchange (LSE), Nasdaq Stockholm (STO) and the New York Stock Exchange (NYSE). The news comes as a blow to London, which up until now had been the primary destination for trading of the £200bn pharma giant’s shares. Read more here 👇 https://www.cityam.com/astrazeneca-to-upgrade-us-listing-in-latest-blow-to-london-stock-exchange/ Get more of City AM 👇 🌐 http://www.cityam.com X(formerly Twitter): http://twitter.com/CityAM Facebook: http://www.facebook.com/cityam Instagram: http://www.instagram.com/city_am LinkedIn: www.linkedin.com/company/cityam Produced by: Simon Hunt, Scarlett Wild, Matt Kenyon #pharma #usa #usnews #ftse100 #politics #news #economy #stocks #financialnews